신장 이식 후 혈관 합병증 (DAN-PTRAIII)
신장 이식 후 혈관 합병증: 전국적 다기관 전향적 연구 - DAN-PTRAIII 연구
- To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
- To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
- To assess whether novel imaging and functional diagnostic methods can predict treatment response.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.
Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.
Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.
Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Mark Reinhard, MD, PhD
- 전화번호: +45 40460321
- 이메일: markrein@rm.dk
연구 연락처 백업
- 이름: Henrik Birn, MD, DMSc
- 이메일: hb@clin.au.dk
연구 장소
-
-
-
Aarhus, 덴마크, 8200
- 모병
- Aarhus University Hospital
-
연락하다:
- Mark Reinhard, MD, PhD
- 이메일: markrein@rm.dk
-
Copenhagen, 덴마크, 2100
- 모병
- Rigshospitalet
-
연락하다:
- Søren S Sørensen, MD, DMSc
- 이메일: Soeren.Schwartz.Soerensen@regionh.dk
-
Odense, 덴마크, 5000
- 모병
- Odense University Hospital
-
연락하다:
- Claus Bistrup, MD, PhD
- 이메일: Claus.Bistrup@rsyd.dk
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.
Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.
설명
Inclusion Criteria:
1. At least one of the following clinical criteria (1 or 2) must be fulfilled:
-
Graft dysfunction, defined by at least one of the following:
- Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
- eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
- Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
-
Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:
- 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).
Together with at least one of the following radiological criteria:
-
CT or MR angiography demonstrating a lumen reduction ≥50%.
-
Doppler ultrasound showing:
- Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
- Acceleration time >70 ms in intrarenal arteries.
2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.
Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:
-
Stenosis ≥70%.
-
Stenosis 50-69% if at least one of the following criteria is met:
- Mean translesional pressure gradient ≥10 mmHg.
- Systolic pressure gradient ≥20 mmHg.
- Renal Pd/Pa ≤0.8.
- If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.
Exclusion Criteria:
- Inability to provide informed consent.
- Concurrent biopsy demonstrating rejection requiring treatment.
- Pregnancy.
- Previous PTA of the same vessel.
- Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Kidney Transplant Recipients
Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common. |
Catheter-based angiography performed in accordance with the study protocol. Measurement of translesional pressure gradients performed in accordance with the study protocol. Intravascular ultrasound (IVUS) performed in accordance with the study protocol. Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in measured glomerular filtration rate (mGFR).
기간: Baseline and 3 months post-PTA.
|
Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline. |
Baseline and 3 months post-PTA.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR).
기간: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline. |
Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
|
Change in home systolic blood pressure.
기간: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline. |
Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
|
|
Change in attended automated office systolic blood pressure.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in unattended automated office systolic blood pressure.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in 24-hour ambulatory systolic blood pressure.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in defined daily dose (DDD) of antihypertensive medications.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in the number of antihypertensive medications.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline. |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
기간: Baseline, 3 months, 12 months, and 24 months post-PTA.
|
Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD). |
Baseline, 3 months, 12 months, and 24 months post-PTA.
|
|
Health status on 12-item Short Form Health Survey (SF-12).
기간: Baseline and 3 months post-PTA.
|
Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. |
Baseline and 3 months post-PTA.
|
|
Number of clinical events after PTA.
기간: 10 years post-PTA.
|
Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:
|
10 years post-PTA.
|
|
Number of adverse events (AEs) occurring within 30 days after the procedure
기간: 30 days post-PTA.
|
All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):
|
30 days post-PTA.
|
|
Doppler ultrasound.
기간: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Invasive pressure measurements across stenoses.
기간: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Intravascular ultrasound.
기간: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
기간: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
|
Functional magnetic resonance imaging.
기간: Baseline and 3 months post-PTA.
|
Diagnostic utility and predictive value for treatment response to PTA. |
Baseline and 3 months post-PTA.
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Mark Reinhard, MD, PhD, Aarhus University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- DAN-PTRAIII
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .